Research summary, original research, 2023

Radiation doses in endovascular revascularisation of lower-extremity arterial diseases

Kaya IÇ, Kaya FA. Cardiovascular journal of Africa. 2023

Read the original paper

In plain language

In 150 patients treated endovascularly for leg arterial disease at one Turkish centre, patient radiation dose (DAP) was higher for pelvic-region work and in patients with higher body mass index (BMI). Staff dose was not measured.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients
Size
n = 150 patients
Where
Turkey
Summary based on
the full text

What it found

  • Patient DAP was higher for pelvic-region interventions than femoropopliteal interventions, in both angioplasty and stenting groups.

    Key figures: angioplasty 23 ± 22 vs 18 ± 27 Gy cm2; stenting 29 ± 18 vs 15 ± 12 Gy cm2; p < 0.05

  • Patient BMI correlated moderately and positively with DAP in both pelvic and femoropopliteal interventions.

    Key figures: pelvic r = 0.601, p = 0.00; femoropopliteal r = 0.512, p = 0.00

  • Ipsilateral popliteal retrograde access had higher fluoroscopy time and DAP than ipsilateral femoral antegrade access.

    Key figures: DAP 25 ± 29 vs 8 ± 11 Gy cm2; FL time p = 0.00, DAP p = 0.005

  • Stenting after angioplasty had longer fluoroscopy time than angioplasty alone; DAP difference was not significant.

    Key figures: FL time 15 ± 9 vs 10 ± 8 min, p = 0.00; DAP 21 ± 17 vs 18 ± 27 Gy cm2, p = 0.069

  • Overall mean DAP and fluoroscopy time across procedures.

    Key figures: DAP 19.5 ± 24 Gy cm2 (median 11); FL time 11.6 ± 8.4 min

Limits to keep in mind

Retrospective single-centre study with two operators measuring only patient DAP and fluoroscopy time; no staff dosimetry or air kerma data were recorded.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.